The market expects Bio-Rad Laboratories (BIO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

Bio-Rad Laboratories, Inc. (BIO) is expected to release first-quarter 2024 results on May 2 after the closing bell.The company posted adjusted earnings per share (EPS) of $3.10 in the last reported quarter, beating the Zacks Consensus Estimate by 5.8%. Bio-Rad beat earnings estimates in three of the trailing four quarters and missed the same in one, the average surprise being 1.93%.Let’s look at how things have shaped up before this announcementFactors at PlayLife ScienceWithin the Life Science business, th ...

Bio-Rad (BIO) has been facing the impact of funding issues in the biopharmaceutical or BioPharma space, macroeconomic headwinds and competitive pressure. The stock carries a Zacks Rank #4 (Sell) currently.Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, where historically, demand for life science products has been strong. This directly correlates with the funding constraints the broader pharmaceutical industry has started to experience. Management stated that ...

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and clinical diagnostics products, for the commercializati ...

Bio-Rad (BIO) suffers due to funding issue within BioPharma, macroeconomic headwinds and competitive pressures. The stock carries a Zacks Rank #4 (Sell) at present.Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, wherein the demand for life science products has been strong historically. This directly correlates with the funding constraints that the broader pharmaceutical industry has started to experience. Management puts forth that BioPharma’s softness has r ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s management will participate in a fireside chat event during Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024, at 2:30 PM Eastern Time (11:30 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s ...

Bio-Rad Laboratories, Inc. (BIO) posted fourth-quarter 2023 adjusted earnings per share (EPS) of $3.10, beating the Zacks Consensus Estimate by 5.8%. However, the bottom line declined 6.3% from the prior-year quarter’s levels.The quarter’s adjustments eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, Restructuring costs, gains/losses from the change in the fair market value of equity securities and gains/losses on equity-method investments.The company’s GAA ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2023 Earnings Conference Call February 15, 2024 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Andy Last - Executive Vice President and COO Simon May - President, Life Science Group Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Dan Leonard - UBS Conor McNamara - RBC Capital Markets Operator Good afternoon, ladies and gentlemen. And welcome to the Bio-Rad Fourth Qu ...

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.0 million and $4.1 million in the consolidated statements of income (loss) for the year ended December 31, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of Dece ...

Bio-Rad Laboratories, Inc. (BIO) is set to release fourth-quarter 2023 results on Feb 15 after the closing bell.The company posted adjusted earnings per share (EPS) of $2.33 in the last reported quarter, missing the Zacks Consensus Estimate by 18.8%. Bio-Rad beat earnings estimates in three of the trailing four quarters and missed the same in one, the average negative surprise being 0.54%.Let’s look at how things have shaped up before this announcement.Factors at PlayLife ScienceThe Life Science segment is ...